SKYE

Business Context and Reporting Period

Company: Skye Bioscience, Inc. (SKYE)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Skye is a clinical-stage biotechnology company developing next-generation molecules targeting G-protein-coupled receptors (GPCRs) to treat obesity and metabolic conditions. Its lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting the cannabinoid receptor 1 (CB1). The company has no approved products and generates no revenue.

Key Financial Metrics

Liquidity: The company raised approximately $83.6 million in net proceeds from private placement equity transactions (PIPE financings) in January and March 2024. Management believes current cash resources are sufficient to fund operations for at least 12 months from the filing date.

Material Changes vs. Prior Period

• Strategic Pivot: In June 2024, the company terminated its ocular program (SBI-100 OE) after the Phase 2a trial failed to meet its primary endpoint. Capital and resources were reallocated entirely to the nimacimab metabolic program.
• Expense Increases: R&D expenses increased 221% year-over-year, driven by the launch of the CBeyond Phase 2a trial for nimacimab and manufacturing costs. G&A expenses increased 126%, primarily due to increased headcount, stock-based compensation, and legal/professional fees related to Nasdaq uplisting and financing.
• Legal Contingency Reversal: The company recorded a $4.2 million gain from a change in estimate for legal contingencies related to the "Cunning Lawsuit" after a successful appeal in the Ninth Circuit Court of Appeals, which vacated a prior judgment and remanded the case for a new trial.
• Cash Recovery: The company recovered $9.0 million in restricted cash (previously posted as an appeal bond) and collected $2.0 million from an insurance carrier settlement related to the Cunning Lawsuit.
• Debt Conversion: A $5.0 million convertible note was converted into common stock in August 2024, eliminating related interest expense.

Guidance, Outlook, and Risks

• Clinical Outlook: The CBeyond Phase 2a trial for nimacimab (monotherapy and combination with GLP-1) is 100% enrolled with approximately 136 patients. Top-line data is expected in late Q3 or early Q4 2025. The trial is planned to be extended to 52 weeks to assess long-term safety and efficacy.
• Capital Needs: While current funds cover operations through 2025, the company will require substantial additional financing to complete Phase 2b studies, Phase 3 trials, and commercialization. An At-The-Market (ATM) equity distribution agreement is in place, though no shares have been sold under it yet.
• Key Risks:
  • Clinical Failure: Nimacimab is the sole product candidate; failure in the Phase 2a trial would be catastrophic to the business.
  • Litigation: The Cunning Lawsuit remains pending for a new trial; final liability is uncertain.
  • Manufacturing: Reliance on third-party contract manufacturing organizations (CMOs) for nimacimab production.
  • Regulatory: Uncertainty regarding FDA approval pathways for CB1 inhibitors and potential safety concerns regarding neuropsychiatric side effects (though nimacimab is designed to be peripherally restricted).

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash sufficiency beyond the stated "12 months" given the high burn rate of clinical trials.
• Legal Exposure: Monitor the status of the remanded Cunning Lawsuit and the potential for renewed liability or settlement costs.
• Capital Raising: Assess the company's ability to raise additional capital in the current market environment to fund Phase 2b and Phase 3 trials.
• Clinical Data: Await the Q3/Q4 2025 top-line readout of the CBeyond trial to validate the safety and efficacy of nimacimab.
• Dilution: Review the impact of outstanding warrants (approx. 11.9 million) and options on future share count and dilution.